13.22

1.05% 0.1497

Atrium Therapeutics Inc (RNA)

Overview News Price History Option Chain Financials Discussions Forecast

Atrium Therapeutics Inc stock is traded at $13.22, with a volume of 132.54K. It is up +1.05% in the last 24 hours and up +3.92% over the past month. Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Previous Close:

$13.07

Open:

$13.08

24h Volume:

132.54K

Relative Volume:

0.09

Market Cap:

$205.26M

Revenue:

$10.73M

Net Income/Loss:

$-455.74M

P/E Ratio:

-5.5662

EPS:

-2.375

Net Cash Flow:

$-502.70M

1W Performance:

+2.62%

1M Performance:

+3.92%

6M Performance:

-81.32%

1Y Performance:

-52.61%

1-Day Range:

$13.07

$13.50

1-Week Range:

$12.75

$13.50

52-Week Range:

$11.95

$73.06

Atrium Therapeutics Inc Stock (RNA) Company Profile

Name

Atrium Therapeutics Inc

Sector

Healthcare (1110)

Industry

Biotechnology (621)

Phone

Address

Employee

391

Twitter

Next Earnings Date

2024-12-07

Latest SEC Filings

RNA's Discussions on Twitter

Compare RNA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RNA Atrium Therapeutics Inc	13.23	202.78M	10.73M	-455.74M	-502.70M	-2.375
VRTX Vertex Pharmaceuticals Inc	433.96	109.09B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	702.73	74.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	805.90	48.64B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	286.10	39.39B	4.29B	577.22M	641.34M	4.2086
ONC Beone Medicines Ltd Adr	309.76	32.38B	5.36B	287.73M	924.18M	2.5229

Atrium Therapeutics Inc Stock (RNA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-11-26	Initiated	Wells Fargo	Overweight
Sep-17-25	Initiated	Roth Capital	Buy
Jul-10-25	Resumed	Goldman	Buy
Jun-24-25	Initiated	Bernstein	Outperform
Jun-17-25	Initiated	Wolfe Research	Outperform
Jun-11-25	Initiated	Raymond James	Strong Buy
Mar-13-25	Initiated	Citigroup	Buy
Mar-12-25	Initiated	BMO Capital Markets	Outperform
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Dec-20-24	Initiated	H.C. Wainwright	Buy
Nov-26-24	Initiated	RBC Capital Mkts	Outperform
Sep-24-24	Initiated	Goldman	Buy
Aug-28-24	Initiated	Barclays	Overweight
May-03-24	Initiated	BofA Securities	Buy
Mar-14-24	Initiated	Cantor Fitzgerald	Overweight
May-22-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-31-23	Downgrade	Evercore ISI	Outperform → In-line
Jul-20-22	Initiated	Chardan Capital Markets	Buy
Jul-12-22	Initiated	Raymond James	Strong Buy
Sep-07-21	Initiated	Evercore ISI	Outperform
Jun-17-21	Initiated	Needham	Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Jul-07-20	Initiated	Cowen	Outperform
Jul-07-20	Initiated	Credit Suisse	Outperform
Jul-07-20	Initiated	SVB Leerink	Outperform
Jul-07-20	Initiated	Wells Fargo	Overweight

View All

Atrium Therapeutics Inc Stock (RNA) Latest News

May 08, 2026

RNA (Atrium Therapeutics) revenue surges 70.8% in Q1, but shares slip as losses persist.Investment Community Signals - newser.com

May 08, 2026

May 06, 2026

What Atrium Therapeutics (RNA) is doing to earn customer loyalty (Nudges Up) 2026-05-06Index Investing - newser.com

May 06, 2026

May 05, 2026

Fierce Biotech Fundraising Tracker '26: Cytospire's $83M for TCEs; Vivacta snags $50M+ series A - Fierce Biotech

May 05, 2026

May 04, 2026